Key result
Pre-hospital administration of clopidogrel, heparin, or a combination of both reduced the risk of in-hospital death in patients with STEMI.
Why the study?
Minimizing the time from symptom onset to treatment improves STEMI care, and early pre-hospital antiplatelet and anticoagulant pharmacotherapy may allow for early effectiveness.
Does pre-hospital administration of clopidogrel and unfractionated heparin reduce in-hospital death and improve left ventricular ejection fraction in patients with STEMI?
Observational (n=573)
No
Does pre-hospital administration of clopidogrel and unfractionated heparin reduce in-hospital death and improve left ventricular ejection fraction in patients with STEMI?
Pre-hospital administration of clopidogrel and unfractionated heparin in STEMI patients is associated with preserved left ventricular ejection fraction and reduced in-hospital mortality.
Answers are grounded in this paper and cite their sources.
Prehospital second antiplatelet was associated with lower risk; leaves open whether routine early use improves STEMI outcomes.
INTRODUCTION: Currently, invasive cardiology techniques are the preferred method of treatment for patients with ST-elevation myocardial infarction (STEMI). Improving the care of patients with STEMI is possible by minimizing the time that elapses from the onset of pain to the start of treatment. As studies indicate, early pharmacotherapy, especially with antiplatelet and anticoagulant medications, allows for their early effectiveness. AIM: To assess the influence of early administration of antiplatelet (clopidogrel) and anticoagulant medications in the pre-hospital period in patients with ST-elevated myocardial infarction on the frequency of in-hospital deaths and on the left ventricular ejection fraction evaluated at hospital discharge. MATERIAL AND METHODS: In this study, a retrospective analysis of 573 patients hospitalized due to ST-segment elevation myocardial infarction in one of Krakow's hospitals from January 2011 to December 2015 (excluding the whole of 2013) was used as a research method. RESULTS: As many as 97% of patients received pre-hospital pharmacotherapy, but only 46.0% of respondents received unfractionated heparin, and 19.2% received clopidogrel. The in-hospital mortality rate was 6.7%, but among patients prehospitally treated with clopidogrel and unfractionated heparin, the in-hospital mortality rate was 1.1%. Prehospital administration of clopidogrel significantly decreased the possibility of reduced left ventricular ejection fraction (OR = 0.27; 95% CI: 0.09-0.90). CONCLUSIONS: Among pre-hospital procedures, only administration of a second antiplatelet drug (clopidogrel) significantly decreased the risk of reduced left ventricular ejection fraction, and administration of clopidogrel or heparin, or a combination of both, significantly decreased the risk of in-hospital death in patients with STEMI.
No takes yet. Share an insight, caveat, or question.
Żurowska-Wolak et al. (2021) conducted an observational in ST-elevation myocardial infarction (STEMI) (n=573). Pre-hospital administration of clopidogrel and/or heparin vs. No pre-hospital administration of antiplatelet or anticoagulant medications was evaluated on In-hospital death (OR 0.32, 95% CI 0.13-0.78). Pre-hospital administration of clopidogrel, heparin, or a combination of both reduced the risk of in-hospital death in patients with STEMI.
Synapse has enriched 10 related papers. Consider them for comparative context: